‚¨’m‚点
’“ŽÔê‚Ì‚²ˆÄ“à![]() |
|
”öú±Šá‰È‰„‰ª•~’n“à‚Ì’“ŽÔê‚ɋ󂫂ª‚È‚¢ê‡‚ÍA ‘æ2’“ŽÔꂪ‚²‚´‚¢‚Ü‚·‚̂ł²—˜—p‚‚¾‚³‚¢B •a‰@•~’n“à’“ŽÔê‚É“ü‚邯‚«‚É‚ÍAŒð’ʈÀ‘S‚Ì‚½‚ß ã}‚̂悤‚ÉM†‚æ‚è‰E‚ɋȂª‚Á‚ÄA–îˆó‚ɉˆ‚Á‚Ä ’“ŽÔê‚É‚¨“ü‚è‚¢‚½‚¾‚‚±‚Æ‚ð‚¨Š©‚ß‚¢‚½‚µ‚Ü‚·B |
![]() ![]() |
![]() ![]() |
![]() ![]() |
![]() |
![]() —[ЧƒfƒCƒŠ[Web@2022/09/06@ŒfÚ |
![]() |
![]() |
77Η«@@ |
![]() |
“ñ\΂ɖ߂Á‚Ă܂·‚Ü‚·Šy‚µ‚Ý‚ðŒ©o‚µ‚Ä‚‚¾‚³‚¢‚Ü‚·‚悤‚¨‹F‚肵‚Ä‚¨‚è‚Ü‚·B |
![]() |
72Î@@ |
![]() |
‚ ‚肪‚Æ‚¤‚²‚´‚¢‚Ü‚µ‚½B—¼Šá‚Æ‚à‚ÉŒ©‚¦‚邿‚¤‚ɂȂç‚êA‚Ü‚·‚Ü‚·Žá•Ô‚Á‚ÄŒ©‚¦‚邿‚¤‚ɂȂ鎖‚ð‚¨‹F‚肵‚Ä‚¨‚è‚Ü‚·B |
![]() |
70‘ã—«@@ |
![]() |
ƒƒbƒZ[ƒW‚ ‚肪‚Æ‚¤‚²‚´‚¢‚Ü‚µ‚½B”’“àáŽèp‚ài‰»‚µ‚ÄŠy‚ɂȂÁ‚Ä‚«‚Ä‚¢‚Ü‚·‚ªAгŽÒ—l‘¤‚©‚ç‚·‚ê‚Αå•ÏS”z‚È‚à‚ÌcƒXƒ^ƒbƒt‚à’š”J‚ɑΉž‚Å‚«‚Ü‚µ‚½‚Å‚µ‚傤‚©BpŒã‚̃PƒA‚àŠæ’£‚Á‚Ä‚¢‚«‚Ü‚µ‚傤B |
@@![]() |
![]() |
ƒƒbƒZ[ƒW‚ ‚肪‚Æ‚¤‚²‚´‚¢‚Ü‚µ‚½B~–[‚Í“`“‚ðŽç‚Á‚Ä‘å•Ï‚¨‚¢‚µ‚¢ƒƒjƒ…[‚ðì‚葱‚¯‚Ä‚¢‚Ü‚·BŽ„‚ª‚¢‚Â‚àŒ³‹C‚Ȃ̂à~–[‚Ì”ü–¡‚µ‚‰h—{ƒoƒ‰ƒ“ƒX‚̂ƂꂽHŽ–‚ÉŽx‚¦‚ç‚ê‚Ä‚¢‚é‚Ì‚©‚à‚µ‚ê‚Ü‚¹‚ñB |
![]() |
|
70‘ã—« @@ |
![]() |
‰@“à‚Ì‚²•]‰¿A‚²Š´‘z‚ð‘‚¢‚Ä‚¢‚½‚¾‚«½‚É‚ ‚肪‚Æ‚¤‚²‚´‚¢‚Ü‚µ‚½B´‘|ŒW‚àƒRƒƒ“ƒg‚ÉŠì‚Ô‚±‚ƂƎv‚¢‚Ü‚·B‚²’ñˆÄ‚̃‰ƒWƒI‚ÆWi-Fi‚ɂ‚«‚Ü‚µ‚Ä‚àŒŸ“¢‚¢‚½‚µ‚Ü‚·B |
@@![]() |
|
70‘ã—« @@ |
![]() |
‘Ò‚¿ŽžŠÔ‚ª’·‚¢‚±‚Æ‚à‘½‚‘å•Ï\‚µ–ó‚ ‚è‚Ü‚¹‚ñB“–‰@‚ÍŠá•a‚ªis‚µ‚Ä‚©‚çŽóf‚³‚ê‚Ä‚‚銳ŽÒ‚³‚ñ‚à‚È‚‚ ‚è‚Ü‚¹‚ñB‚±‚Ì‚½‚ßfŽ@‚ÉŽèŠÔŽæ‚邱‚Æ‚ª‚ ‚èA‹°k‚µ‚Ä‚¨‚è‚Ü‚·B‘Îô‚ÉŽíXŽŽs‚µ‚Ä‚¢‚邯‚±‚ë‚Å‚·B —Ž–’·fŽ@‚ª¬ŽG‚µ‚Ä‚¢‚鎞‚ÍA‘¼‚̈ãŽt‚̑Ήž‚ő҂¿ŽžŠÔ’Zk‚ɑΉž‚µ‚Ä‚¨‚è‚Ü‚·B ‚Ü‚½VŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚ÌŽžŠú‚Å‚·‚Ì‚ÅAŽÔ‚Ì’†‚őҋ@‚Å‚«‚é•û‚͑ҋ@‚µ‚Ä‚¢‚½‚¾‚¢‚½‚èAŒg‘єԆ‚𒸂¢‚Ä‚¨ŒÄ‚Ñ‚µ‚½‚è‚·‚邿‚¤‚É€”õ‚µ‚Ä‚¨‚è‚Ü‚·BŽó•t‚É‚¨\‚µ•t‚¯‚‚¾‚³‚¢B |
![]() |
Šw‰ï–¼ | ”•\“ú | ‰‰‘è–¼ |
“ú–{—ΓàáŠw‰ï | 2023”N 9ŒŽ9“ú |
—Ž‹û—Γàá‚ÌPrecision Medicinei‰¼j |
Šw‰ï–¼ | ”•\“ú | ‰‰‘è–¼ |
APAOiƒAƒWƒA‘¾•½—mŠá‰ÈŠw‰ïj | 2023”N 2ŒŽ25“ú |
Severe Phenotype of Exfoliation Patients With CYP39A1 Mutations |
“ú–{—Õ°Šá‰ÈŠw‰ï | 2022”N 10ŒŽ15“ú |
—Ž‹û—Γàá‚ÌŽ¡—Ãí—ª |
ARVOiŽ‹Šo‚ÆŠá‰ÈŠwŒ¤‹†‹¦‰ï‰ï‹cj | 2022”N 5ŒŽ5“ú |
Effects of endogenous substances on albumin-binding of diclofenac and site inhibitors in the aqueous humor of patients undergoing cataract surgery. |
APGCiƒAƒWƒA‘¾•½—m—Γàá‰ï‹cj2021 | ƒ|ƒXƒ^[”•\ | Tanito microhook ab interno trabeculotomy for primary open angle glaucoma, primary angle closure glaucoma and exfoliation glaucoma. |
APGCiƒAƒWƒA‘¾•½—m—Γàá‰ï‹cj2021 | 2021”N 6ŒŽ6“ú |
Update on genetics of exfoliation syndrome |
—Γàáf—ÃUpdate | 2020”N 11ŒŽ24“ú |
—Ž‹û—Γàá‚Ì•a‘Ô‚Æ‘Îô |
“ú–{—ΓàáŠw‰ï | 2020”N 10ŒŽ2“ú`4“ú |
u—Γàáˆâ“`Žqv‚ɂ‚¢‚ẴVƒ“ƒ|ƒWƒEƒ€ |
“ú–{—Õ°Šá‰ÈŠw‰ï | 2019”N 10ŒŽ26“ú |
Identification of Candidate miRNA Biomarkers for Glaucoma |
“ú–{—ΓàáŠw‰ï | 2019”N 9ŒŽ6“ú |
‹³ˆçu‰‰ u—Γàá•aŒ^‚²‚Ƃ̃Aƒvƒ[ƒ`v |
ARVO iŽ‹Šo‚ÆŠá‰ÈŠwŒ¤‹†‹¦‰ï‰ï‹cj |
2019”N 4ŒŽ28“ú`5ŒŽ2“ú |
Targeted assessment of the chromosome-15 locus identifies a potential protective role for ISLR coding variants in exfoliation syndrome |
“ú–{Šá‰ÈŠw‰ï‘‰ï | 2019”N 4ŒŽ21“ú |
ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[ uf’f‚ÆŽ¡—ẪAƒbƒvƒf[ƒg@‘±”—Γàá@g—Ž‹û—Γàá‚ÌŠî‘b‚Æ—Õ°gv |
“ú–{—Õ°Šá‰ÈŠw‰ï | 2018”N 10ŒŽ10“ú`14“ú |
ERMB_ŒoŠá‰È•׋‰ï Eu‚—îŽÒ‚Ì—Ž‹û—Γàá@—Õ°‚Æ•ªŽqˆâ“`Šwv |
“ú–{—ΓàáŠw‰ï | 2018”N 9ŒŽ14“ú`16“ú |
u—Ž‹ûÇŒóŒQ‚¨‚æ‚Ñ—Ž‹û—Γàá‚É‚¨‚¯‚éˆâ“`Žq‰ð͂̓¹’ö‚ÆŽ¡—Âւ̓W–]v |
ARVO iŽ‹Šo‚ÆŠá‰ÈŠwŒ¤‹†‹¦‰ï‰ï‹cj |
2018”N 4ŒŽ28“ú`5ŒŽ5“ú |
Poster: Genetic analysis reveal significant and consistent pairwise interactions between common non-coding LOXL1 polymorphisms. |
APGC iƒAƒWƒA‘¾•½—m—Γàá‰ï‹cj |
2018”N 4ŒŽ12“ú`15“ú |
Cautions and Complications in cataract extraction in eyes with exfoliation syndrome |
APAO iƒAƒWƒA‘¾•½—mŠá‰ÈŠw‰ïj |
2018”N 2ŒŽ9“ú`11“ú |
Clinical Applicability of Genetics in Exfoliation Syndrome |
“ú–{—Õ°Šá‰ÈŠw‰ï | 2017”N 10ŒŽ12“ú`15“ú |
RMB_ŒoŠá‰È•׋‰ï |
“ú–{—ΓàáŠw‰ï | 2017”N 9ŒŽ29“ú`10ŒŽ1“ú |
u—Ž‹ûÇŒóŒQ‚ÉŠÖ˜A‚·‚éLysyl oxidase-like 1 (LOXL1)‚É‚¨‚¯‚érare variant ’Tõv |
WGCi¢ŠE—Γàá‰ï‹cj | 2017”N 6ŒŽ28“ú`7ŒŽ1“ú |
Clinical applicability of genetics in exfoliation syndrome |
‹ãBŠá‰ÈŠw‰ï | 2017”N 5ŒŽ21“ú |
ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u—Ž‹ûÇŒóŒQ‚ƗΓàáv |
APAO iƒAƒWƒA‘¾•½—mŠá‰ÈŠw‰ïj |
2017”N 3ŒŽ1“ú`5“ú |
Ocular and systemic manifestations of exfoliation syndrome |
“ú–{Šá‰ÈŠw‰ï‘‰ï | 2017”N 4ŒŽ6“ú`9“ú |
—Ž‹ûÇŒóŒQ‘å‹K–̓Rƒz[ƒg‚ɑ΂·‚éƒQƒmƒ€ƒƒCƒhŠÖ˜A‰ðÍ |
§882-0056
‹{茧‰„‰ªŽs‰ª•x’¬125”Ô’n
TEL 0982-20-8900